三阴型乳腺癌治疗策略的最新进展
摘要
复发频繁,且在复发后死亡率高,预后差。虽然化疗是 TNBC 患者的主要治疗方式,但疗效仍然有限。因此,及时开发新
的治疗方法和靶点至关重要,且迫在眉睫。根据 TNBC 中表达的特定分子和信号通路,目前已出现了多种靶向治疗策略。
此外,免疫检查点抑制剂和抗体 - 药物偶联物也在临床中被广泛探索。
关键词
全文:
PDF参考
[1]Mohamed RF, Bakri HM, Abdelfattah ON, Eid S. Does
bevacizumab carry a hope for metastatic triple-negative breast
cancer in the era of immunotherapy? Anticancer Drugs 2022;
33:e604-e609.
[2]Bahhnassy A, Mohanad M, Shaarawy S, et al. Transforming
growth factor-beta, insulin-like growth factor I/insulin-like
growth factor I receptor and vascular endothelial growth factor-A:
prognostic and predictive markers in triple-negative and non-
triple-negative breast cancer. Mol Med Rep 2015; 12:851-64.
[3]Hamilton E, Kimmick G, Hopkins J, et al. Nab-paclitaxel/
bevacizumab/carboplatin chemotherapy in first-line triple negative
metastatic breast cancer. Clin Breast Cancer 2013; 13:416-20.
[4]GerberB,LoiblS,EidtmannH,et al. Neoadjuvant
bevacizumab and anthracycline-taxane-based chemotherapy
in 678 triple-negative primary breast cancers; results from the
geparquinto study (GBG 44). Ann Oncol 2013; 24:2978-84.
[5]van Rossum AGJ, Mandjes IAM, van Werkhoven E, et
al. Carboplatin-Cyclophosphamide or Paclitaxel without or with
Bevacizumab as First-Line Treatment for Metastatic Triple-
Negative Breast Cancer (BOOG 2013-01). Breast Care (Basel)
2021; 16:598-606.
[6]Yang JZ, Bao YF, Ci YJ, Zhu JJ. Efficacy of neoadjuvant
chemotherapy combined with low-dose Apatinib in the treatment
of triple negative breast cancer. Asian J Surg 2023; 46:2703-
2704.
[7]Fan W, Ding J, Zhong W. Efficacy and Safety of Third-
Line Apatinib plus Chemotherapy in Metastatic Triple-Negative
Breast Cancer Patients: A Multicenter, Retrospective, Cohort
Study. Tohoku J Exp Med 2023; 260:13-20.
[8]Liu J, He M, Ou K, et al. Efficacy and safety of apatinib
combined with dose-dense paclitaxel and carboplatin in
neoadjuvant therapy for locally advanced triple-negative breast
cancer: A prospective cohort study with propensity-matched
analysis. Int J Cancer 2024; 154:133-144.
[9]Huang W, Wang C, Shen Y, et al. A real-world study
of the effectiveness and safety of apatinib-based regimens in
metastatic triple-negative breast cancer. BMC Cancer 2024;
24:39.
[10]Yi M, Dong B, Qin S, et al. Advances and perspectives of
PARP inhibitors. Exp Hematol Oncol 2019; 8:29.
[11]Zhu S, Wu Y, Song B, et al. Recent advances in targeted
strategies for triple-negative breast cancer. J Hematol Oncol 2023;
16:100.
[12] 胡洋 , 张清媛 . PARP 抑制剂治疗 BRCA1/2 突变转
移性乳腺癌的研究进展 . 实用肿瘤学杂志 2021; 35:184-187.
[13]Robson ME, Im SA, Senkus E, et al. OlympiAD extended
follow-up for overall survival and safety: Olaparib versus
chemotherapy treatment of physician’s choice in patients with a
germline BRCA mutation and HER2-negative metastatic breast
cancer. Eur J Cancer 2023; 184:39-47.
[14]Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant
Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast
Cancer. N Engl J Med 2021; 384:2394-2405.
[15]Litton JK, Rugo HS, Ettl J, et al. Talazoparib in Patients
with Advanced Breast Cancer and a Germline BRCA Mutation. N
Engl J Med 2018; 379:753-763.
[16]Lee KH, Sohn J, Goodwin A, et al. Talazoparib Versus
Chemotherapy in Patients with HER2-negative Advanced
Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in
Asian Countries: Exploratory Subgroup Analysis of the Phase III
EMBRACA Trial. Cancer Res Treat 2021; 53:1084-1095.
[17]Litton JK, Scoggins ME, Hess KR, et al. Neoadjuvant
Talazoparib for Patients With Operable Breast Cancer With a
Germline BRCA Pathogenic Variant. J Clin Oncol 2020; 38:388-
394.
[18]Agostinetto E, Losurdo A, Nader-Marta G, et al. Progress
and pitfalls in the use of immunotherapy for patients with triple
negative breast cancer. Expert Opin Investig Drugs 2022; 31:567-
591.
[19] 李萍 , 朱程君 , 孙月 , et al. 三阴性乳腺癌含免疫检
查点抑制剂治疗方案的Ⅲ期临床研究解析 . 中国临床研究
2022; 35:1205-1210.
[20]Nanda R, Chow LQ, Dees EC, et al. Pembrolizumab in
Patients With Advanced Triple-Negative Breast Cancer: Phase Ib
KEYNOTE-012 Study. J Clin Oncol 2016; 34:2460-7.
[21]Adams S, Schmid P, Rugo HS, et al. Pembrolizumab
monotherapy for previously treated metastatic triple-negative
breast cancer: cohort A of the phase II KEYNOTE-086 study.
Ann Oncol 2019; 30:397-404.
[22]Adams S, Loi S, Toppmeyer D, et al. Pembrolizumab
monotherapy for previously untreated, PD-L1-positive,
metastatic triple-negative breast cancer: cohort B of the phase II
KEYNOTE-086 study. Ann Oncol 2019; 30:405-411.
[23]Schmid P, Salgado R, Park YH, et al. Pembrolizumab
plus chemotherapy as neoadjuvant treatment of high-risk, earlystage triple-negative breast cancer: results from the phase 1b
open-label, multicohort KEYNOTE-173 study. Ann Oncol 2020;
31:569-581.
[24]Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab
plus chemotherapy versus placebo plus chemotherapy for
previously untreated locally recurrent inoperable or metastatic
triple-negative breast cancer (KEYNOTE-355): a randomised,
placebo-controlled, double-blind, phase 3 clinical trial. Lancet
2020; 396:1817-1828.
[25]Schmid P, Cortes J, Dent R, et al. Event-free Survival
with Pembrolizumab in Early Triple-Negative Breast Cancer. N
Engl J Med 2022; 386:556-567.
[26]Mittendorf EA, Zhang H, Barrios CH, et al. Neoadjuvant
atezolizumab in combination with sequential nab-paclitaxel
and anthracycline-based chemotherapy versus placebo and
chemotherapy in patients with early-stage triple-negative breast
cancer (IMpassion031): a randomised, double-blind, phase 3 trial.
Lancet 2020; 396:1090-1100.
[27]Schmid P, Rugo HS, Adams S, et al. Atezolizumab
plus nab-paclitaxel as first-line treatment for unresectable,
locally advanced or metastatic triple-negative breast cancer
(IMpassion130): updated efficacy results from a randomised,
double-blind, placebo-controlled, phase 3 trial. Lancet Oncol
2020; 21:44-59.
[28]Miles D, Gligorov J, Andre F, et al. Primary results from
IMpassion131, a double-blind, placebo-controlled, randomised
phase III trial of first-line paclitaxel with or without atezolizumab
for unresectable locally advanced/metastatic triple-negative breast
cancer. Ann Oncol 2021; 32:994-1004.
[29]Chu Y, Zhou X, Wang X. Antibody-drug conjugates for
the treatment of lymphoma: clinical advances and latest progress.
J Hematol Oncol 2021; 14:88.
[30]Qiu S, Zhang J, Wang Z, et al. Targeting Trop-2 in
cancer: Recent research progress and clinical application. Biochim
Biophys Acta Rev Cancer 2023; 1878:188902.
[31]Jeon Y, Jo U, Hong J, et al. Trophoblast cell-surface
antigen 2 (TROP2) expression in triple-negative breast cancer.
BMC Cancer 2022; 22:1014.
[32]Cortesi M, Zanoni M, Maltoni R, et al. TROP2 (trophoblast
cell-surface antigen 2): a drug target for breast cancer. Expert
Opin Ther Targets 2022; 26:593-602.
[33] 张娣 , 黎立喜 , 马飞 . 戈沙妥珠单抗在乳腺癌及其
他实体瘤中临床应用的研究进展 . 癌症 2022; 41:253-258.
[34]Bardia A, Messersmith WA, Kio EA, et al. Sacituzumab
govitecan, a Trop-2-directed antibody-drug conjugate, for
patients with epithelial cancer: final safety and efficacy results
from the phase I/II IMMU-132-01 basket trial. Ann Oncol 2021;
32:746-756.
[35]Bardia A, Tolaney SM, Punie K, et al. Biomarker
analyses in the phase III ASCENT study of sacituzumab govitecan
versus chemotherapy in patients with metastatic triple-negative
breast cancer. Ann Oncol 2021; 32:1148-1156.
[36]Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab
Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J
Med 2021; 384:1529-1541.
[37]Okajima D, Yasuda S, Maejima T, et al. Datopotamab
Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate,
Demonstrates Potent Antitumor Activity by Efficient Drug Delivery
to Tumor Cells. Mol Cancer Ther 2021; 20:2329-2340.
[38]Shastry M, Jacob S, Rugo HS, Hamilton E. Antibodydrug conjugates targeting TROP-2: Clinical development in
metastatic breast cancer. Breast 2022; 66:169-177.
(1 摘要 Views, 1 PDF Downloads)
Refbacks
- 当前没有refback。